NCT00648986

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails

Single Center, Open-Label, Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Columbia University · Academic / Other
• Sex: All
• Age: 18 Years – 76 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether topical tazarotene (Tazorac), a receptor-selective synthetic retinoid that normalizes epidermal differentiation, ameliorates signs and symptoms of brittle nails.

Detailed description

"Brittle nails," referring to nails that chip, peel, or split excessively, occur in up to 30% of women and 15% of men, with highest prevalence among the elderly. Treatment of brittle nails involves restoration and maintenance of a normal degree of nail plate hydration by minimizing exposure to dehydrating chemicals and by use of moisturizers, such as alpha-hydroxy acids. Retinoids are vitamin A analogs that play a role in skin cell differentiation and proliferation. Tazarotene is a topical receptor-selective synthetic retinoid that normalizes epidermal differentiation and reduces the influx of inflammatory cells into the skin. In this single-center, open-label trial, subjects applied tazarotene to the nails twice daily for 24 weeks. Signs and symptoms were rated by the investigators and subjects during treatment and 12 weeks after discontinuation.

Conditions

• Brittle Nails

Interventions

Type	Name	Description
DRUG	Tazorac	All patients were to apply topical tazarotene (Tazorac) twice daily to all affected fingernails for 24 weeks.

Timeline

• Start date: 2005-08-01
• Primary completion: 2006-12-01
• Completion: 2006-12-01
• First posted: 2008-04-01
• Last updated: 2014-07-02

Locations

1 site across 1 country: United States